JP2019501214A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501214A5
JP2019501214A5 JP2018543288A JP2018543288A JP2019501214A5 JP 2019501214 A5 JP2019501214 A5 JP 2019501214A5 JP 2018543288 A JP2018543288 A JP 2018543288A JP 2018543288 A JP2018543288 A JP 2018543288A JP 2019501214 A5 JP2019501214 A5 JP 2019501214A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
independently
amino acid
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543288A
Other languages
English (en)
Japanese (ja)
Other versions
JP6855496B2 (ja
JP2019501214A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060996 external-priority patent/WO2017083306A1/en
Publication of JP2019501214A publication Critical patent/JP2019501214A/ja
Publication of JP2019501214A5 publication Critical patent/JP2019501214A5/ja
Priority to JP2021043495A priority Critical patent/JP7109613B2/ja
Application granted granted Critical
Publication of JP6855496B2 publication Critical patent/JP6855496B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543288A 2015-11-09 2016-11-08 抗cd22抗体−メイタンシンコンジュゲートおよびその使用方法 Active JP6855496B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021043495A JP7109613B2 (ja) 2015-11-09 2021-03-17 抗cd22抗体-メイタンシンコンジュゲートおよびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562252985P 2015-11-09 2015-11-09
US62/252,985 2015-11-09
PCT/US2016/060996 WO2017083306A1 (en) 2015-11-09 2016-11-08 Anti-cd22 antibody-maytansine conjugates and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021043495A Division JP7109613B2 (ja) 2015-11-09 2021-03-17 抗cd22抗体-メイタンシンコンジュゲートおよびその使用方法

Publications (3)

Publication Number Publication Date
JP2019501214A JP2019501214A (ja) 2019-01-17
JP2019501214A5 true JP2019501214A5 (https=) 2019-07-04
JP6855496B2 JP6855496B2 (ja) 2021-04-07

Family

ID=58695155

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018543288A Active JP6855496B2 (ja) 2015-11-09 2016-11-08 抗cd22抗体−メイタンシンコンジュゲートおよびその使用方法
JP2021043495A Active JP7109613B2 (ja) 2015-11-09 2021-03-17 抗cd22抗体-メイタンシンコンジュゲートおよびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021043495A Active JP7109613B2 (ja) 2015-11-09 2021-03-17 抗cd22抗体-メイタンシンコンジュゲートおよびその使用方法

Country Status (14)

Country Link
US (1) US12102689B2 (https=)
EP (1) EP3373937B1 (https=)
JP (2) JP6855496B2 (https=)
KR (1) KR102783230B1 (https=)
CN (1) CN108463226B (https=)
AU (1) AU2016354009B2 (https=)
CA (1) CA3004584A1 (https=)
DK (1) DK3373937T3 (https=)
ES (1) ES2908470T3 (https=)
IL (1) IL259186B2 (https=)
MX (1) MX2018005785A (https=)
RU (1) RU2744895C2 (https=)
WO (1) WO2017083306A1 (https=)
ZA (1) ZA201803476B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3373937B1 (en) * 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Anti-cd22 antibody-maytansine conjugates and methods of use thereof
KR20200117992A (ko) * 2017-12-11 2020-10-14 트리페이스 리서치 앤드 디벨로프먼트 쓰리 코포레이션 항-cd22 항체-메이탄신 컨쥬게이트, 그것의 조합, 및 사용 방법
CN119896746A (zh) * 2019-01-23 2025-04-29 R.P.谢勒技术有限责任公司 用于抗体-药物缀合物的含有糖苷的肽接头
EP4037673A4 (en) * 2019-10-04 2023-08-16 R.P. Scherer Technologies, LLC ANTI-CD25 ANTIBODY-MAYTANSINE CONJUGATES AND METHODS OF USE THEREOF
WO2021087248A1 (en) * 2019-10-31 2021-05-06 R.P. Scherer Technologies, Llc Anti-cd37 antibody-maytansine conjugates and methods of use thereof
CN116783208A (zh) * 2020-11-20 2023-09-19 R.P.谢勒技术有限责任公司 用于抗体-药物缀合物的糖苷双裂解接头
AU2022230398A1 (en) * 2021-03-03 2023-08-31 R.P. Scherer Technologies, Llc Branched linkers for antibody-drug conjugates and methods of use thereof
US20250121090A1 (en) * 2021-07-30 2025-04-17 R.P. Scherer Technologies, Llc Antibody-Drug Conjugates and Methods of Use Thereof

Family Cites Families (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES324609A1 (es) 1966-03-24 1966-12-16 Patronato De Investigacien Cie Procedimiento para la preparaciën de indolil-alquil hidrazinas
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5666928A (en) 1979-11-05 1981-06-05 Hitachi Ltd Pulse generating circuit
US4352795A (en) 1981-01-29 1982-10-05 Warner-Lambert Company 7-β-D-Arabinofuranosyl-7H-pyrrolo[2,3-d]pyrimidine compounds and methods for their production
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
ZW10887A1 (en) 1986-06-25 1987-10-28 Injectall Ltd Improvements in apparatus for injecting substances into liquids
DK8189A (da) 1988-01-12 1989-07-13 Bunge Australia Antigen-antistof-konjugater, deres fremstilling og anvendelse
DE3815826A1 (de) 1988-05-09 1989-11-23 Henkel Kgaa Verfahren zur herstellung von vicinal diacyloxysubstituierten verbindungen
US5470829A (en) 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
IL90193A (en) 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US5650388A (en) 1989-11-22 1997-07-22 Enzon, Inc. Fractionated polyalkylene oxide-conjugated hemoglobin solutions
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NL194941C (nl) 1990-02-15 2003-08-04 Cordis Corp Werkwijze voor het aanbrengen van een fysiologisch actieve verbinding op een substraatoppervlak.
US5275838A (en) 1990-02-28 1994-01-04 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5171264A (en) 1990-02-28 1992-12-15 Massachusetts Institute Of Technology Immobilized polyethylene oxide star molecules for bioapplications
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
FR2672053B1 (fr) 1991-01-30 1993-04-23 Atochem Polyether bloc amides, leur procede de synthese.
CA2082160C (en) 1991-03-06 2003-05-06 Mary M. Bendig Humanised and chimeric monoclonal antibodies
FR2673946B1 (fr) 1991-03-15 1993-05-28 Atochem Polyether bloc amides, leur procede de synthese.
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン,インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
AU660534B2 (en) 1992-02-13 1995-06-29 Novo Nordisk A/S Polyethylene or polypropylene glycol containing polymer
CA2130436C (en) 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
AU7109494A (en) 1993-06-16 1995-01-03 Enzon, Inc. Conjugated biodhesives
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
AU2826495A (en) 1994-06-02 1996-01-04 Enzon, Inc. Method of solubilizing substantially water insoluble materials
US5730990A (en) 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5756593A (en) 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
CA2226299A1 (en) 1995-08-11 1997-02-27 Dendritech, Inc. Hyper comb-branched polymer conjugates
WO1997013529A1 (en) 1995-10-13 1997-04-17 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services Immunotoxin containing a disulfide-stabilized antibody fragment
WO1997022371A1 (en) 1995-12-18 1997-06-26 Collagen Corporation Crosslinked polymer compositions and methods for their use
US6900304B2 (en) 1996-01-31 2005-05-31 The Regents Of The University Of California Emission ratiometric indicators of phosphorylation
US8669074B2 (en) 1996-01-31 2014-03-11 The Regents Of The University Of California Chimeric phosphorylation indicator
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US7541034B1 (en) 1997-03-20 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-vegf 항체
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
JP3835827B2 (ja) 1997-05-02 2006-10-18 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ,アズ リプレゼンティッド バイ ザ セクレタリーオブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 悪性細胞に対する、oncタンパク質を含む、免疫毒素
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
GB9712892D0 (en) 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
WO1999030727A1 (en) 1997-12-17 1999-06-24 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル,コーポレイション 近位の反応性基を持つポリ(エチレングリコール)誘導体
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
DE69925133T2 (de) 1998-08-27 2006-01-19 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
AU6059699A (en) 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
DE60042785D1 (de) 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
DK1455839T3 (da) 1999-10-08 2013-05-06 Nektar Therapeutics Heterobifunktioneller poly(ethylenglycol)-derivater og fremgangsmåder til fremstilling heraf
AU2001281463A1 (en) 2000-03-16 2001-09-24 The Regents Of The University Of California Chemoselective ligation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6911535B2 (en) 2000-03-22 2005-06-28 Solvlink Biosciences Biomolecule/polymer conjugates
US20050201981A1 (en) 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7355012B2 (en) 2001-09-26 2008-04-08 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
WO2003072736A2 (en) 2002-02-21 2003-09-04 Duke University Reagents and treatment methods for autoimmune diseases
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US7456260B2 (en) 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US8188116B2 (en) 2002-09-04 2012-05-29 Vanderbilt University Agents for therapy efficacy monitoring and deep tissue imaging
US7754884B2 (en) 2005-01-03 2010-07-13 Vanderbilt University Targeted, NIR imaging agents for therapy efficacy monitoring, deep tissue disease demarcation and deep tissue imaging
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
WO2005023818A2 (en) 2003-09-10 2005-03-17 Gpc Biotech Ag Heterobicyclic compounds as pharmaceutically active agents
CA2542220A1 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
CN1560035A (zh) 2004-03-12 2005-01-05 沈阳药科大学 5-羟基吲哚-3-羧酸脂类衍生物
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
KR20070037719A (ko) 2004-06-30 2007-04-06 노파르티스 아게 항종양제로서의 항체와 듀오카르마이신 유도체의컨쥬게이트
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CA2583764C (en) 2004-10-25 2009-06-09 Ligand Pharmaceuticals, Inc. Thrombopoietin activity modulating compounds and methods
US7255012B2 (en) 2004-12-01 2007-08-14 Rosemount Inc. Process fluid flow device with variable orifice
AU2006210724A1 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
JP5142707B2 (ja) 2005-02-08 2013-02-13 一般財団法人化学及血清療法研究所 抗体の改良方法
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
TW200745096A (en) 2005-08-23 2007-12-16 Organon Nv Indole derivatives
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP2009532336A (ja) 2006-03-06 2009-09-10 メディミューン,エルエルシー ヒト化抗cd22抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用
EP2032606B1 (en) 2006-05-30 2013-11-27 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
CN101490087B (zh) * 2006-05-30 2013-11-06 健泰科生物技术公司 抗体和免疫偶联物及其用途
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
WO2008019303A2 (en) 2006-08-04 2008-02-14 Enanta Pharmaceuticals, Inc. Pyridazinonyl macrocyclic hepatitis c serine protease inhibitors
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
WO2009120611A2 (en) 2008-03-27 2009-10-01 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
JP5798489B2 (ja) 2009-01-12 2015-10-21 ストロ バイオファーマ, インコーポレイテッド インビトロタンパク質合成システムを用いて非天然アミノ酸をタンパク質に選択的に導入するためのモノチャージシステム
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2416765B1 (en) 2009-04-06 2016-03-30 PTC Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
SG181893A1 (en) 2009-12-22 2012-08-30 Hoffmann La Roche Sequence dependent aggregation
KR20110093055A (ko) 2010-02-11 2011-08-18 다우어드밴스드디스플레이머티리얼 유한회사 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
CA2819373A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
WO2012097333A2 (en) * 2011-01-14 2012-07-19 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
US20170049906A1 (en) 2012-05-21 2017-02-23 President And Fellows Of Harvard College Translocation of non-natural chemical entities through anthrax protective antigen pore
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
US9439972B2 (en) 2012-09-10 2016-09-13 Ad Lunam Labs, Inc. Antifungal serum
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) * 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
CN105722859B (zh) 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN115504924A (zh) * 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
KR102486180B1 (ko) 2014-06-06 2023-01-11 레드우드 바이오사이언스 인코포레이티드 항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
JP6785777B2 (ja) 2015-02-05 2020-11-18 アール.ピー. シェーラー テクノロジーズ エルエルシー 活性化ホルミルグリシン生成酵素ならびにその生成方法及び使用方法
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗hla‐drまたは抗trop‐2抗体と微小管阻害剤、parp阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド3‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
EP3373937B1 (en) 2015-11-09 2021-12-22 R.P. Scherer Technologies, LLC Anti-cd22 antibody-maytansine conjugates and methods of use thereof
KR20200117992A (ko) 2017-12-11 2020-10-14 트리페이스 리서치 앤드 디벨로프먼트 쓰리 코포레이션 항-cd22 항체-메이탄신 컨쥬게이트, 그것의 조합, 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2019501214A5 (https=)
JP2019142870A5 (https=)
RU2018120696A (ru) Конъюгаты анти-cd22 антитело-майтансин и способы их применения
AU2018387418B2 (en) Bicyclic peptide ligands specific for EphA2
JP2016153410A5 (https=)
ES2918425T3 (es) Conjugados de anticuerpo-fármaco
CN109195631B (zh) 具有鹅膏毒肽的衍生物作为药物的抗体药物缀合物
AU2020210919B2 (en) Glycoside-containing peptide linkers for antibody-drug conjugates
RU2019105549A (ru) Гидрофильные саморазрушающиеся линкеры и их конъюгаты
JP2022518743A5 (https=)
JP2012529433A5 (https=)
EP2913064A1 (en) Branched drug-linker conjugates for the coupling to biological targeting molecules
JP2017537893A5 (https=)
JP2014506135A5 (https=)
RU2020123953A (ru) Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и конъюгаты антитело-лекарственное средство, включающие их
JP2024041959A5 (https=)
JP2022530524A5 (https=)
JP2015524796A5 (ja) 細胞毒性剤と細胞結合受容体との共役体
RU2017134348A (ru) Конъюгаты антитело-лекарственное средство на основе криптофицина с новыми саморасщепляющимися линкерами
AR113258A1 (es) Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
JP2016526574A5 (https=)
RU2017103462A (ru) Материалы и способы, связанные с линкерами для применения в конъюгатах лекарственного средства и белка
RU2019131252A (ru) Пептидные вакцины на основе pd1 человека и их применение
JP2023511184A5 (https=)
AU2019335513B2 (en) Alpha(v)beta(6) integrin-binding peptides and methods of use thereof